Exenatide Nasal

This novel formulation of exenatide for diabetes patients is in the early investigative phase and continues to show potential.

© 2010 Amylin Pharmaceuticals, Inc. All rights reserved. The SYMLIN mark, SymlinPen mark, and BYETTA mark are registered trademarks of Amylin Pharmaceuticals, Inc. The SYMLIN Support Program mark and BYETTA By Your Side mark are service marks of Amylin Pharmaceuticals, Inc.

Home
Terms of Use
Privacy
Site Map